ArticlemedRxiv : the preprint server for health sciences2025
BrainAge moderates associations between Alzheimer's disease biomarkers and cognitive decline: a meta-analysis across A4/LEARN, HABS and ADNI cohorts.
Jorge Garcia Condado, Hannah M Klinger, Colin Birkenbihl, Madison Cuppels, Annie Liu, Iñigo Tellaetxe Elorriaga, Mabel Seto, Gillian T Couglan, Michael J Properzi, Dorene M Rentz and 12 more
Abstract readPreprint
In one paragraphArticle in medRxiv : the preprint server for health sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
22 authors.
Jorge Garcia CondadoComputational Neuroimaging Lab, BioBizkaia Health Research Institute, Barakaldo, Spain.ORCID 0000-0002-9463-1924 Hannah M KlingerMassachusetts General Hospital, Harvard Medical School, Boston MA, USA.
Madison CuppelsMassachusetts General Hospital, Harvard Medical School, Boston MA, USA.
Annie LiuMassachusetts General Hospital, Harvard Medical School, Boston MA, USA.
Iñigo Tellaetxe ElorriagaComputational Neuroimaging Lab, BioBizkaia Health Research Institute, Barakaldo, Spain.ORCID 0009-0001-1832-5183 Gillian T CouglanMassachusetts General Hospital, Harvard Medical School, Boston MA, USA.
Michael J ProperziMassachusetts General Hospital, Harvard Medical School, Boston MA, USA.
Aaron P SchultzMassachusetts General Hospital, Harvard Medical School, Boston MA, USA.
Asier ErramuzpeComputational Neuroimaging Lab, BioBizkaia Health Research Institute, Barakaldo, Spain.ORCID 0000-0002-9402-2184 Keith A JohnsonMassachusetts General Hospital, Harvard Medical School, Boston MA, USA.
Brian C HealyMassachusetts General Hospital, Harvard Medical School, Boston MA, USA.
Jesus M CortesComputational Neuroimaging Lab, BioBizkaia Health Research Institute, Barakaldo, Spain.ORCID 0000-0002-9059-8194 Michael DonohueAlzheimer's Therapeutic Research Institute, University of Southern California, Los Angeles CA, USA.ORCID 0000-0001-6026-2238 Funding
Alzheimer's Disease Neuroimaging Initiative - SupplementU01AG024904 · NIA · NORTHERN CALIFORNIA INSTITUTE RES &EDUC · PI WEINER, MICHAEL W · 2004 to 2015
$121.0MRECRUITMENT COREU19AG010483 · NIA · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI FELDMAN, HOWARD · 2013 to 2020
$80.6MVascular factors, physical activity, and inflammation as modulators of neurodegenerative and cognitive trajectories (Project 2)P01AG036694 · NIA · MASSACHUSETTS GENERAL HOSPITAL · PI Hyun-Sik Yang · 2010 to 2026
$50.2MAnti-Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4) Open-Label Extension StudyR01AG063689 · NIA · BRIGHAM AND WOMEN'S HOSPITAL · PI AISEN, PAUL S., SPERLING, REISA A. · 2019 to 2024
$30.8MBuilding predictive algorithms to identify resilience and resistance to Alzheimer's diseaseR01AG079142 · NIA · MASSACHUSETTS GENERAL HOSPITAL · PI Rachel Frances Buckley, Michael C Donohue · 2023 to 2026
$4.0MThe inactive X: discovering sex genes that influence female vulnerability to Alzheimer's diseaseDP2AG082342 · NIA · MASSACHUSETTS GENERAL HOSPITAL · PI Rachel Frances Buckley · 2022 to 2026
$2.5MMenopause, hormone therapy and Alzheimer's disease clinicopathology: An in vivo perspectiveK99AG083063 · NIA · MASSACHUSETTS GENERAL HOSPITAL · PI COUGHLAN, GILLIAN THERESA · 2024 to 2025
$269kNIA NIH HHS DP2 AG082342NIA NIH HHS K99 AG083063NIA NIH HHS P01 AG036694NIA NIH HHS R01 AG063689NIA NIH HHS R01 AG079142NIA NIH HHS U01 AG024904NIA NIH HHS U19 AG010483
6 · The paper itselfAbstract
BrainAge delta, the difference between a person's predicted brain age and their chronological age, is a promising marker of the accumulation of neurodegeneration that may increase vulnerability to Alzheimer's disease (AD). We examined whether BrainAge delta moderates the relationship between AD biomarkers and longitudinal cognitive decline performing a meta-analysis across three cohorts (2,279 cognitively unimpaired [CU]; 416 with mild cognitive impairment [MCI]). Higher BrainAge delta was linked to faster decline in CU (β = -0.13 [-0.21, -0.06], p = 0.018, I
Identifiers
PMID40672483
PMCPMC12265764
What OpenQuestion holds
Textmetadata
LicenceCC BY-ND
Read underepoch 390